Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer (Q36617556)

15 August 2017

Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer (English)

1 reference

15 August 2017

1 reference

1 reference

Houston SJ

1

1 reference

15 August 2017

Plunkett TA

2

1 reference

15 August 2017

Barnes DM

3

1 reference

15 August 2017

Smith P

4

1 reference

15 August 2017

Rubens RD

5

1 reference

15 August 2017

Miles DW

6

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 March 1999

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

79

1 reference

15 August 2017

7-8

1 reference

15 August 2017

1220-1226

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6690196

15 August 2017

0 references

cites work

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362250

Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362250

ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362250

Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362250

Stability of HER-2/neu expression over time and at multiple metastatic sites

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362250

Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362250

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362250

Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362250

An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362250

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362250

Growth factor receptors and the progression of breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362250

Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362250

HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362250

HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362250

Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362250

Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362250

Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362250

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

20 September 2018

1 reference

12 December 2020

Regulation of estrogen receptor concentration and activity by an erbB/HER ligand in breast carcinoma cell lines

1 reference

12 December 2020

Seasonal variation in the secretion of mammotrophic hormones in normal women and women with previous breast cancer

1 reference

12 December 2020

Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein

1 reference

12 December 2020

Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers

1 reference

12 December 2020

Increased use of immunohistochemistry for oestrogen receptor measurement in mammary carcinoma: the need for quality assurance

1 reference

12 December 2020

Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland

1 reference

12 December 2020

Estrogen receptors and response to endocrine therapy and cytotoxic chemotherapy in advanced breast cancer

1 reference

12 December 2020

Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study

1 reference

12 December 2020

Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers

1 reference

12 December 2020

Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients

1 reference

12 December 2020

The neu-oncogene product in serum and tissue of patients with breast carcinoma

1 reference

12 December 2020

ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer

1 reference

12 December 2020

The predictive power of semiquantitative immunohistochemical assessment of p53 and c-erb B-2 in lymph node-negative breast cancer

1 reference

12 December 2020

neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690196

7 January 2021

Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690196

7 January 2021

Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690196

7 January 2021

c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690196

7 January 2021

c-erbB-2 oncoprotein detected by automated quantitative immunocytochemistry in breast carcinomas correlates with patients' overall and disease-free survival

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690196

7 January 2021

Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690196

7 January 2021

The assessment of histological differentiation in breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690196

7 January 2021

c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690196

7 January 2021

Cell biological factors associated with the response of breast cancer to systemic treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690196

7 January 2021

Antihormone treatment of stage IV breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690196

7 January 2021

Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690196

7 January 2021

Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690196

7 January 2021

Identifiers

DOI

10.1038/SJ.BJC.6690196

1 reference

15 August 2017

1 reference

15 August 2017

1 reference